| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 189.95 | 9.2% | 20.7% |
| Total Income | 189.95 | 9.2% | 20.7% |
| Expenditure | 166.21 | 3.5% | 37.6% |
| PBT | 19.41 | 128.6% | 46.4% |
| Net Profit | 14.68 | 100.5% | 58.0% |
| OPM | 12.50% | 4.85pp | 10.74pp |
| NPM | 7.73% | 3.52pp | 14.45pp |
| EPS | 0.42 | 100.0% | 59.2% |
TransMedics Reports Q2 2026 Financial Results
05 Aug 2026 · 5 Aug, 1:40 am
Summary
TransMedics Group reported a 21% year-over-year increase in total revenue for the second quarter of 2026, reaching $189.9 million. This growth was driven by a 16% rise in product revenue and a significant 29% increase in service revenue. While gross margin slightly decreased to 60% from 61% year-over-year, the company raised its full-year 2026 revenue guidance to a range of $737 million to $757 million. Management highlighted record revenue and accelerating service growth as key achievements for the quarter.
Key Highlights
- 1
Total revenue increased by 21% to $189.9 million in the second quarter of 2026 compared to the second quarter of 2025.
- 2
Product revenue grew 16% to $111.2 million, while Service revenue increased by 29% to $78.8 million in Q2 2026.
- 3
Net income for the second quarter of 2026 was $14.7 million, or $0.41 per fully diluted share.
- 4
Adjusted net income for the second quarter of 2026 was $16.2 million, or $0.44 per fully diluted share.
- 5
The company raised the low end of its full-year 2026 revenue guidance to a range of $737 million to $757 million.
- 6
On July 1, 2026, TransMedics completed a strategic investment in PAD Aviation to establish an organ transplantation air logistics network in Europe.
Management Comments
Waleed Hassanein
The second quarter was a defining one for TransMedics: record revenue, accelerating service growth, and sequential gross margin expansion, all as we invested aggressively in our strategic priorities. Let me be direct about how we see our business: we are building TransMedics to remain a growth company in the near, mid, and long terms. We are deploying capital behind four distinct growth opportunities that we believe will drive substantial revenue growth with a compelling operating profile at scale. Our confidence is derived from our team’s proven track record of converting investment into results, quarter after quarter. It is also grounded in the unparalleled nature of our offering: the life-saving impact of our OCS technology, the reach of our NOP platform, and the extraordinary people who deliver it. Our mission has not changed — expand access and improve outcomes for every patient waiting for an organ transplant. We are more inspired by what lies ahead than at any point in our history.
Informational and educational content only. Not investment advice.